AZ drug combo misses the mark in late-stage lung cancer study

An AstraZeneca immunotherapy has failed to meet its goal in a late-stage study involving patients with advanced non-small cell lung cancer.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news